No Data
Shandong Lukang Pharmaceutical (600789.SH): The company and its holding subsidiaries participate in the national pharmaceutical centralized procurement and are expected to win the bid.
On December 19, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that the company and its controlling subsidiary, ShanDong Lukang Pharmaceutical Group Saiter Co., Ltd. (referred to as "Saiter Company"), participated in the bidding for the tenth nationwide centralized Pharmaceutical procurement organized by the Joint Procurement Office. The company and Saiter Company intend to have some of their Pharmaceuticals selected in this centralized procurement.
Is Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Latest Stock Performance A Reflection Of Its Financial Health?
Shandong Lukang Pharmaceutical (600789.SH) 2024 interim equity distribution: distributed 0.02 yuan per share, with the equity registration on December 17.
Shandong Lukang Pharmaceutical (600789.SH) announced the profit distribution plan for the first half of 2024, with this profit distribution based on the scheme...
Shandong Lukang Pharmaceutical Gets Approval for Anticoagulant for Knee, Hip Replacement Surgery
China Aprpoves Lukang Pharma Unit's Supplementary Drug Application for Heart Injection
Investors are paying attention to the progress of FT606. Shandong Lukang Pharmaceutical did not directly respond to the production time | Live coverage of the earnings conference
① The company's new synthetic biotechnology material product FT606 has attracted much attention. ② The pharmaceutical industry was in the traditional off-season in the third quarter, leading to a decline in the company's Q3 performance. ③ In the earnings conference, a questioner claiming to be an investor expressed dissatisfaction with the lack of interaction.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
